SimaWuqin
2021-11-22
It is time! gogo
FDA accepts for review Obseva's linzagolix application for uterine fibroids
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":872784096,"tweetId":"872784096","gmtCreate":1637575426515,"gmtModify":1637575426515,"author":{"id":3568459082756365,"idStr":"3568459082756365","authorId":3568459082756365,"authorIdStr":"3568459082756365","name":"SimaWuqin","avatar":"https://static.tigerbbs.com/6bc36ec0fc750ba6d2fd4bb2d77c4c09","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>It is time! gogo</p></body></html>","htmlText":"<html><head></head><body><p>It is time! gogo</p></body></html>","text":"It is time! gogo","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/872784096","repostId":1150150145,"repostType":2,"repost":{"id":"1150150145","kind":"news","pubTimestamp":1637574586,"share":"https://www.laohu8.com/m/news/1150150145?lang=&edition=full","pubTime":"2021-11-22 17:49","market":"us","language":"en","title":"FDA accepts for review Obseva's linzagolix application for uterine fibroids","url":"https://stock-news.laohu8.com/highlight/detail?id=1150150145","media":"seekingalpha","summary":"Obseva(NASDAQ:OBSV)announces that the New Drug Application (NDA) for linzagolix for the management o","content":"<p>Obseva(NASDAQ:OBSV)announces that the New Drug Application (NDA) for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted for review by the U.S. FDA.</p>\n<p>The submission is based on data from the two Phase 3 PRIMROSE trials.</p>\n<p>The FDA has set a target action date of September 13, 2022 for this NDA under PDUFA.</p>\n<p>Linzagolix has a differentiated profile and if approved, would be the first and only GnRH receptor antagonist with flexible dosing options for uterine fibroids, including a low dose option to address the needs of women who cannot or do not want to take hormones.</p>\n<p>Last month, Obseva inked partnership with Syneos Health to support commercialization of linzagolix in U.S. and EU.</p>\n<p>OBSV submitted linzagolix NDA in U.S. for uterine fibroids in September 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA accepts for review Obseva's linzagolix application for uterine fibroids</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA accepts for review Obseva's linzagolix application for uterine fibroids\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 17:49 GMT+8 <a href=https://seekingalpha.com/news/3773107-fda-accepts-for-review-obsevas-linzagolix-application-for-uterine-fibroids><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Obseva(NASDAQ:OBSV)announces that the New Drug Application (NDA) for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted...</p>\n\n<a href=\"https://seekingalpha.com/news/3773107-fda-accepts-for-review-obsevas-linzagolix-application-for-uterine-fibroids\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3773107-fda-accepts-for-review-obsevas-linzagolix-application-for-uterine-fibroids","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1150150145","content_text":"Obseva(NASDAQ:OBSV)announces that the New Drug Application (NDA) for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted for review by the U.S. FDA.\nThe submission is based on data from the two Phase 3 PRIMROSE trials.\nThe FDA has set a target action date of September 13, 2022 for this NDA under PDUFA.\nLinzagolix has a differentiated profile and if approved, would be the first and only GnRH receptor antagonist with flexible dosing options for uterine fibroids, including a low dose option to address the needs of women who cannot or do not want to take hormones.\nLast month, Obseva inked partnership with Syneos Health to support commercialization of linzagolix in U.S. and EU.\nOBSV submitted linzagolix NDA in U.S. for uterine fibroids in September 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":816,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":13,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/872784096"}
精彩评论